Search for: "Solvay Pharmaceuticals Inc" Results 1 - 20 of 50
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
22 Dec 2015, 9:00 am
The case was originally filed on June 10, 2003, by relators John King and Tammy Drummond, naming several pharmaceutical companies as defendants including Solvay Pharmaceuticals Inc. [read post]
22 Dec 2015, 9:00 am
The case was originally filed on June 10, 2003, by relators John King and Tammy Drummond, naming several pharmaceutical companies as defendants including Solvay Pharmaceuticals Inc. [read post]
22 Dec 2015, 9:00 am
The case was originally filed on June 10, 2003, by relators John King and Tammy Drummond, naming several pharmaceutical companies as defendants including Solvay Pharmaceuticals Inc. [read post]
28 May 2014, 10:31 am by Don T. Hibner, Jr.
In April 1999, Solvay Pharmaceuticals, LLC (“Solvay”) filed a New Drug Application (“NDA”) with the Food and Drug Administration (“FDA”) seeking approval to commercially market a testosterone replacement gel (“AndroGel”). [read post]
1 Mar 2014, 6:22 am by Legal Reader
Before the drug was approved by the FDA in 2000, Solvay Pharmaceuticals Inc. acquired Unimed Pharmaceuticals, Inc. and subsequently brought AndroGel to market. [read post]
26 Jun 2013, 5:30 am by RatnerPrestia
The patentee, Solvay Pharmaceuticals, agreed to license various generic challengers of its patent for a testosterone supplement, AndroGel, which would have permitted the challengers to enter the market at a future date but prior to patent expiry. [read post]
25 Jun 2013, 6:52 am
Back in 1999, Solvay Pharmaceuticals had filed a New Drug Application for a drug named AndroGel. [read post]
17 Jun 2013, 1:21 pm by Lyle Denniston
  The initial patent had run out, but the U.S. licensee — Solvay Pharmaceuticals, Inc. [read post]
11 Apr 2013, 4:57 am by Eric Guttag
FTC Sues Regarding AndroGel Patent SettlementThe Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition to Solvay’s branded testosterone-replacement drug AndroGel, a prescription pharmaceutical with annual sales of… [read post]
11 Mar 2013, 12:49 pm by John J. Sullivan
Mar. 5, 2013), the plaintiffs were qui tam relators who’d sparked investigations by state AGs into alleged False Claims Act violations by the pharmaceutical manufacturer, Abbot Products, Inc., which was later acquired by Solvay Pharmaceuticals, Inc.. [read post]
23 Oct 2012, 6:30 am by Matthew Gilpin
Watson Pharmaceuticals, Inc.[6] The petition seeks to overturn the Eleventh Circuit’s dismissal of the FTC’s challenge to a reverse payment settlement agreement between Solvay Pharmaceuticals, Inc., and several generic manufacturers over a drug called Androgel. [read post]
12 Jul 2012, 7:57 am by mstein03
(“Solvay”), agreed to make over $20 million annual payments to the generic challengers Watson Pharmaceuticals, Inc., Par Pharmaceuticals, Inc., and Paddock Laboratories, Inc. [read post]